title: Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after Hodgkin lymphoma.
abstract: Bronchioloalveolar carcinoma (BAC) is a subset of lung adenocarcinoma that has a distinct clinical presentation, tumor biology, response to therapy, and prognosis compared with other subtypes of non-small-cell lung carcinoma. BAC disproportionately affects women, never-smokers, and is characterized by growth along alveolar septae without evidence of stromal, vascular, or pleural invasion. Microscopically, BACs have been divided into mucinous, nonmucinous, and mixed types. We describe a case of young female who received radiation therapy to the mediastinum and chemotherapy for Hodgkin lymphoma and now develops mucinous bronchioalveolar adenocarcinoma of the left lung which to the best of our knowledge has not been previously described after radiotherapy and chemotherapy for Hodgkin lymphoma. The tumor cells express Galectin-3, CD138, p16INK4a, thyroid transcription factor-1, cytokeratin 7, epithelial membrane antigen, carcinoembryonic antigen, E-cadherin, neuron-specific enolase, and S100 whereas no expression of cytokeratin 20, calretinin, and CDX2 is seen.
authors.affiliation: Faculty of Medicine and Health Sciences, Pathology Department, United Arab Emirates University, Al Ain, UAE. suhaila@uaeu.ac.ae
authors.forename: Suhail
authors.initials: S
authors.lastname: Al-Salam
authors.forename: Moueid
authors.initials: M
authors.lastname: Al-Ashari
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D000328:Adult; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000096:biosynthesis*; D005260:Female; D037502:Galectin 3 / Q000096:biosynthesis*; D006689:Hodgkin Disease / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D016609:Neoplasms, Second Primary / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D009687:Nuclear Proteins / Q000096:biosynthesis*; D053668:Syndecan-1 / Q000096:biosynthesis*; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors / Q000096:biosynthesis*
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D037502:Galectin 3; C000614412:NKX2-1 protein, human; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; C508241:SDC1 protein, human; D053668:Syndecan-1; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors